Comparison of clinical data between groups with and without cardiac events
| Cardiac events group (n=34) | No cardiac events group (n=144) | p Value | |
|---|---|---|---|
| Age (years) | 58.2±14.6 | 55.1±14.6 | 0.312 |
| Gender (male/female) | 17/17 | 90/54 | 0.147 |
| NYHA(I/II/III/IV) | 19/9/4/2 | 113/22/4/5 | 0.326 |
| Body mass index (kg/m2) | 22.7±7.0 | 22.8±6.1 | 0.855 |
| Systolic blood pressure (mm Hg) | 132.8±25.9 | 129.3±21.0 | 0.519 |
| Diastolic blood pressure (mm Hg) | 73.3±19.2 | 75.7±13.3 | 0.572 |
| Heart rate (beats/min) | 68.4±12.8 | 68.5±12.8 | 0.929 |
| Diabetes mellitus | 5 (14.7%) | 20 (13.8%) | 0.590 |
| Hypertension | 9 (26.4%) | 34 (23.6%) | 0.466 |
| Dyslipidemia | 5 (14.7%) | 21 (14.6%) | 0.583 |
| Atrial fibrillation | 12 (35.2%) | 31 (21.5%) | 0.213 |
| Ventricular tachycardia/ventricular fibrillation | 10 (29.4%) | 37 (25.7%) | 0.439 |
| Underlying heart diseases | 0.203 | ||
| Ischaemic heart diseases | 1 (3.0%) | 14 (9.7%) | |
| Non-ischaemic heart diseases | 33 (97.0%) | 131 (90.3%) | |
| Diuretics | 18 (53.0%) | 38 (26.4%) | 0.025 |
| ACE-I | 6 (17.6%) | 25 (17.4%) | 0.571 |
| ARB | 5 (14.7%) | 23 (15.9%) | 0.557 |
| Calcium channel blockers | 15 (44.5%) | 39 (27.1%) | 0.126 |
| β-Blockers | 14 (41.2%) | 57 (39.6%) | 0.520 |
| Nitrates | 5 (14.7%) | 12 (8.3%) | 0.234 |
| Digitalis | 7 (16.2%) | 25 (17.4%) | 0.438 |
| Statins | 3 (8.8%) | 14 (9.7%) | 0.592 |
| Antiarrhythmic drugs | 8 (23.5%) | 40 (27.8%) | 0.440 |
| Antiplatelets | 18 (53.0%) | 69 (47.9%) | 0.439 |
| Plasma BNP (pg/dl) | 126.4±101.1 | 129.0±197.2 | 0.932 |
| Haemoglobin (mg/dl) | 13.1±2.1 | 13.1±1.9 | 0.935 |
| Creatinine (mg/dl) | 1.1±0.9 | 1.0±1.4 | 0.891 |
| Sodium (mmol/l) | 139.6±3.0 | 138.8±14.2 | 0.760 |
The p values are from t test or Fisher's exact test.
Values are shown as mean±one SD or for categorical is number of observation and (percentages).
ACE-I, ACE-inhibitors; ARB, angiotensin-receptor blockers; BNP, brain natriuretic peptide.